New research suggests that individuals who stop using new GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass far faster than those who halt traditional lifestyle programs.
Findings released in a leading health publication points out that while obese people often shed about a fifth of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"Users purchasing such medications must be aware of the danger of rapid rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb.
Such speed of recovery suggests a reversion to pre-treatment weight within about one and a half years.
Weighing Treatments
The study, which looked at 37 of studies involving over 9,000 of participants, contrasted the effects of these new drugs with older methods.
Scientists note that individuals who shed pounds through dieting generally have a slower weight regain—approximately 0.1 kg a month—post-intervention.
Understanding the Quick Regain
Experts suggest the mode of action of the drugs is key to understanding the accelerated weight return.
These medications mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of GLP-1 levels several times higher than normal may cause the body to produce less of its endogenous GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication results in appetite is uncontrolled, making excessive eating far more likely."
An Ongoing Condition?
The NHS advise the jabs for people with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts contend that, given the significant potential of weight regain, the treatment is often ongoing.
This opinion is reinforced by drug manufacturers, who state that the results "highlight the long-term character of excess weight," akin to managing diseases like diabetes.
Patient Testimonies
Individuals who have stopped the medication describe a powerful return of appetite.
"I experienced something that goes on and I was suddenly starving," said one woman.
This challenge is exacerbated if individuals have not developed lasting lifestyle or habit modifications during therapy.
Widespread Use
Recent estimates suggest that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is greater among women compared to men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Finally, researchers caution that while the jabs are potent tools for shedding pounds, they are not a standalone solution and maintained weight loss relies on integrated behavioural support.
